Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.71 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | CCKAR | P32238 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | GHSR | Q92847 | 1/20 | 0.71 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.71 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300966 | 1.00 | UGT1A1 (0.71) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL8162986 | 1.00 | UGT1A1 (0.71) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL30018952 | 1.00 | UGT1A1 (0.71) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL16298849 | 0.97 | UGT1A1 (0.73) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL2178325 | 0.97 | UGT1A1 (0.69) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL10034686 | 0.96 | UGT1A1 (0.69) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL8224259 | 0.95 | UGT1A1 (0.66) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL893599 | 0.94 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL16866221 | 0.93 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6157358 | 0.93 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890121-B2 | Process for preparing atazanavir sulphate | CIPLA LIMITED (IN) | 2018-02-13 | — | — | US | disclosed |
| WO-2017042735-A1 | AMORPHOUS FORM OF A HIV PROTEASE INHIBITOR | GRANULES INDIA LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
| US-20160002166-A1 | Process for Preparing Atazanavir Sulphate | CIPLA LIMITED (IN) | 2016-01-07 | — | — | US | disclosed |
| US-20150320731-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| EP-1755596-B1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-20150202191-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2015-07-23 | — | — | US | disclosed |
| US-20130266648-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-8513428-B2 | Process for preparing atazanavir bisulfate and novel forms | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011080562-A1 | NOVEL AZA-PEPTIDES CONTAINING 2,2-DISUBSTITUTED CYCLOBUTYL AND/OR SUBSTITUTED ALKOXY BENZYL DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-07-07 | — | — | WO | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | OXYRANE (UK) LIMITED (UK) | 2009-10-29 | — | — | US | disclosed |
| US-20090203630-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090076097-A1 | DEUTERIUM-ENRICHED ATAZANAVIR | PROTIA, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076097-A1 | DEUTERIUM-ENRICHED ATAZANAVIR | PROTIA, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009002826-A2 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1697348-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005108349-A2 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005061487-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076097-A1 | DEUTERIUM-ENRICHED ATAZANAVIR | SAMHD1, ADAR, APOBEC3A | UGT1A1 1398/4885MLNR 3361/4885NR1I2 2115/4885 |
| US-20160002166-A1 | Process for Preparing Atazanavir Sulphate | SAMHD1, TPMT, ASH2L | UGT1A1 277/4885MLNR 1118/4885NR1I2 3800/4885 |
| US-20130266648-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | UGT1A1 2307/4885MLNR 3723/4885NR1I2 3691/4885 |
| US-20150320731-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-20090203630-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | GTF3C3, PRSS3, GTF3C4 | UGT1A1 1255/4885MLNR 3933/4885NR1I2 3857/4885 |
| US-20150202191-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | SAMHD1, TYMS, COASY | UGT1A1 309/4885MLNR 3692/4885NR1I2 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.